Oramed Pharmaceuticals (NASDAQ:ORMP) Releases Quarterly Earnings Results, Misses Expectations By $0.59 EPS

Oramed Pharmaceuticals (NASDAQ:ORMP) issued its quarterly earnings data on Thursday. The biotechnology company reported ($0.16) EPS for the quarter, missing analysts’ consensus estimates of $0.43 by ($0.59), Zacks reports.

Oramed Pharmaceuticals Trading Down 2.4%

Shares of ORMP opened at $4.03 on Friday. Oramed Pharmaceuticals has a 12-month low of $2.25 and a 12-month high of $5.47. The firm has a market capitalization of $167.65 million, a P/E ratio of 0.98 and a beta of 1.31. The firm has a 50-day moving average price of $4.38 and a 200 day moving average price of $4.05.

Analyst Ratings Changes

A number of research analysts have issued reports on ORMP shares. Weiss Ratings raised Oramed Pharmaceuticals from a “hold (c+)” rating to a “buy (b-)” rating in a report on Friday, October 23rd. Wall Street Zen cut Oramed Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Saturday, November 7th. One analyst has rated the stock with a Buy rating. Based on data from MarketBeat.com, Oramed Pharmaceuticals has a consensus rating of “Buy”.

Insider Transactions at Oramed Pharmaceuticals

In other news, COO Joshua Hexter sold 30,000 shares of the stock in a transaction that occurred on Thursday, October 1st. The shares were sold at an average price of $4.51, for a total value of $135,300.00. Following the completion of the sale, the chief operating officer owned 1,328,130 shares of the company’s stock, valued at $5,989,866.30. This represents a 2.21% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Avraham Gabay sold 20,000 shares of the firm’s stock in a transaction that occurred on Thursday, October 1st. The stock was sold at an average price of $4.51, for a total transaction of $90,200.00. Following the sale, the chief financial officer owned 861,076 shares of the company’s stock, valued at $3,883,452.76. This represents a 2.27% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 20.77% of the stock is owned by insiders.

About Oramed Pharmaceuticals

Oramed Pharmaceuticals Inc. is a clinical-stage pharmaceutical company developing oral drug-delivery technologies. Its platform is designed to protect protein-based medicines as they pass through the digestive system and support their absorption, with the aim of delivering medicines by mouth that have traditionally been given by injection. The company’s research has focused on oral treatments for metabolic conditions, including ORMD-0801, an oral insulin candidate, and an oral GLP-1 candidate. These products are investigational; Oramed does not market them as approved treatments.